M24.1 M94.26
Conditions
Interventions
Group 1: Patients who have undergone matrix augmented bone marrow stimulation with HyaloFast® due to focal chondromalacia III-IV Preoperatively, the following general patient data are determined:
- De
leukocytes, Hb) via the routine laboratory (no additional blood samples)
The patient is also asked to fill out a self-disclosure form about his or her limitations caused by the knee joint or his or h
Sponsors
Medizinische Hochschule Hannover
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: - focal chondromalacia III-IV" with the performance of a matrix augmented bone marrow stimulation including revision surgery - Male and female patients aged between 18 years and 50 years
Exclusion criteria
Exclusion criteria: - Accompanying pathologies such as surgically treated patellar stability - BMI > 40 - History of knee infections - Rheumatological joint disease of the knee joint - ASA 3-4 - Known basic neurological disease with mobility impairment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| After treatment with Hyalofast® in the area of the retropatellar cartilage, the patients' complaints, measured by the IKDC subjective score, decrease by at least 8.5 points from pre-op to post-op. | — |
Secondary
| Measure | Time frame |
|---|---|
| descriptive recording: VAS regarding pain, VAS regarding pain, defect filling determined by MRT | — |
Countries
Germany
Contacts
Public ContactYvonne Noll
Orthopädische Klinik der Medizinischen Hochschule Hannover im Diakovere Annastift, Leitung Klinisches Studienmanagement
Outcome results
None listed